Vaclav Volrab / Shutterstock.com
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.
Whether it is to replenish innovator pharmaceutical companies’ diminishing new product pipelines or because of the allure of new platform technologies, the life sciences industry has been an active sector for transactions of various kinds.
These transactions have come in the form of partnerships, joint ventures, licences, and mergers and acquisitions. Life sciences companies typically rely on patent and regulatory exclusivity to recover the enormous costs associated with developing and bringing a product to market before generic or biosimilar competition drives profits down.
This means that intellectual property (in particular, patents) is often one of the most valuable assets of a life sciences company, particularly an early stage company, which does not have a revenue stream. Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Karen Mangasarian, Ryan Murphey, Ropes & Gray, freedom to operate, patent, trademark, copyright, FTO, USPTO, PTE, FDA,